Merck with an investment of US$715 million plans for the expansion of Antibody-drug Conjugates (ADC) manufacturing. The new manufacturing facility will be located in Madison, Wisconsin, USA.
Antibody-drug Conjugates (ADC) manufacturing facility will be designed with an area covering 6,500-square-meter. This new facility will be engaged in the production of high-potent active pharmaceutical ingredients (HPAPI) and ADC manufacturing capabilities.
The project designed with a large area will be one of the largest manufacturing facilities to manage single-digit nanogram occupational exposure limit materials and support the continuous flow manufacturing of HPAPIs. Moreover, the new facility will be an addition to the first commercial ADC facility in North America specialised in ADC bio-conjugation, active pharmaceutical ingredients, excipient and adjuvants manufacturing.
The completion of the project is scheduled to be in the mid of 2022 and is expected to create 50 full-time jobs in the starting of 2021.